Technology | Image Guided Radiation Therapy (IGRT) | February 27, 2017

ViewRay Receives FDA 510(k) Clearance for MRIdian Linac

Henry Ford Health Center and Barnes-Jewish Hospital will be first two U.S. hospitals to offer MRI-guided radiation therapy clinically via linear accelerator

ViewRay, MRIdian Linac system, FDA 510k approval, MRI-guided radiation therapy

February 27, 2017 — ViewRay Inc. announced that the company received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market the MRIdian Linac system, the company's next-generation linear accelerator-based magnetic resonance imaging (MRI)-guided radiation therapy system.

The first two MRIdian Linac systems in the United States are expected to be installed at Henry Ford Hospital in Detroit and Barnes-Jewish Hospital at Washington University in St. Louis.

"Radiation oncologists have long awaited the availability of a clinical system that integrates MR-imaging with linac radiation delivery, as this is a major breakthrough in improving the efficacy of radiation therapy for patients," said Benjamin Movsas, M.D., chairman of radiation oncology at the Henry Ford Cancer Institute in Michigan. "At the Henry Ford Cancer Institute, we're proud to be among the first centers to offer treatment with MRIdian Linac. The ability to see what's happening inside the body while the patient is undergoing radiation therapy and ensure the radiation continually remains on target is a huge leap forward and will help us to improve patient outcomes."

"With MRI-guided radiation therapy, we're able to watch the movement of tumors and organs in the body as radiation is being delivered and adapt the dose of radiation in real time, to help ensure the maximum dose reaches the tumor and that surrounding healthy tissue is spared," said Sasa Mutic, Ph.D., director of radiation oncology physics at Washington University School of Medicine. "This technology helps us treat tumors such those in the lung, liver and pancreas where increased precision is important due to nearby organs and other critical structures."

Read a feature story from the June 2016 issue of ITN on MRI-guided radiation therapy.

For more information: www.viewray.com

Related Content

Figure 1. Doppler flows in subpleural consolidation shows smoothly dilated branching arteries

Figure 1. Doppler flows in subpleural consolidation shows smoothly dilated branching arteries 

Feature | Radiology Imaging | September 17, 2020 | By Robert Bard, M.D. PC, DABR, FASLM
COVID-19 is routinely studied using...
Data from latest research presented at the ESMO Virtual Congress 2020 suggests COVID-19 pandemic halts cancer care and damages oncologists' wellbeing

Getty Images

News | Coronavirus (COVID-19) | September 17, 2020
September 17, 2020 — Delays and cancellation of cancer treatments and other safety measures undertaken to minimize th
 A cardiac MRI is effective in identifying inflammation of the heart muscle in athletes and can help determine when those who have recovered from COVID-19 can safely return to play in competitive sports, according to a new study by researchers at The Ohio State University Wexner Medical Center.

Getty Images

News | Cardiac Imaging | September 14, 2020
September 14, 2020 — A...
All intensive care unit equipment, including ventilators, pumps, and monitoring devices, as well as the point-of-care magnetic resonance image operator and bedside nurse, remained in the room. All equipment was operational during scanning.

All intensive care unit equipment, including ventilators, pumps, and monitoring devices, as well as the point-of-care magnetic resonance image operator and bedside nurse, remained in the room. All equipment was operational during scanning. Image courtesy of JAMA Neurology

News | Magnetic Resonance Imaging (MRI) | September 11, 2020
September 11, 2020 — A portable, low-field...
Six months after deployment, the no-show rate of the predictive model was 15.9%, compared with 19.3% in the preceding 12-month preintervention period — corresponding to a 17.2% improvement from the baseline no-show rate (p < 0.0001). The no-show rates of contactable and noncontactable patients in the group at high risk of appointment no-shows as predicted by the model were 17.5% and 40.3%, respectively (p < 0.0001).

Weekly outpatient MRI appointment no-show rates for 1 year before (19.3%) and 6 months after (15.9%) implementation of intervention measures in March 2019, as guided by XGBoost prediction model. Squares denote data points. Courtesy of the  American Roentgen Ray Society (ARRS), American Journal of Roentgenology (AJR)

News | Artificial Intelligence | September 10, 2020
September 10, 2020 — According to ARRS’
Vantage Galan with Advanced intelligent Clear-IQ Engine (AiCE) provides high-quality images and fast exam times

Coronal orbit images: Left original and right with AiCE.

News | Magnetic Resonance Imaging (MRI) | September 09, 2020
September 9, 2020
the Contrast Media Injectors Market is estimated to be USD 1.3 billion in 2020 and  projected to reach $1.9B by 2025, at a CAGR of 7.4% between 2020 and 2025

Getty Images

News | Contrast Media Injectors | September 02, 2020
September 2, 2020 — According to the new market research report "...
The global pediatric imaging market size is expected to reach $12.2 billion by 2027, registering a CAGR of 7.6% over the forecast period, according to a new report by Grand View Research, Inc.

Getty Images

News | Pediatric Imaging | August 26, 2020
August 26, 2020 — The global ...
Single-dose radiotherapy replaces need for extra hospital visits, with benefits for patient safety and well-being

Getty Images

News | Women's Health | August 20, 2020
August 20, 2020— For most women with early breast cancer